Cargando empresa
Keep exploring
The themes Palatin Technologies is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B US$A+
EXELExelixis, Inc.16,8B US$A+
JAZZJazz Pharmaceuticals plc15,5B US$A
TECHBIO-Techne Corp11,4B US$A+
HALOHalozyme Therapeutics, Inc.11,4B US$A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct 2026CAGraded C, now A
Cómo gana dinero
- Licensing and research collaborations
Compite con
Qué vende4
Next-generation long-acting MC4R peptide agonist
An experimental peptide medicine being developed as a once-weekly injection for obesity, with a focus on rare conditions involving appetite and weight regulation.
Next-generation oral MC4R small-molecule agonist
An experimental medicine taken by mouth that Palatin is preparing for further development for rare obesity disorders.
PL9643
An experimental peptide medicine for dry eye disease. Palatin licensed development and commercialization rights to Altanispac Labs.
PL8177
An experimental oral peptide medicine studied for inflammatory bowel diseases, including ulcerative colitis; Palatin is seeking a development partner.
Quién se lo compra2
- Pharmaceutical companies that license drug candidates or development rights and may pay upfront fees, research funding, milestone payments and royalties.
- Biopharmaceutical partners, including Boehringer Ingelheim and Altanispac Labs, which take responsibility for developing or commercializing licensed programs.
En qué se apoya y qué podría romperlo
De qué depende el negocio
- 1Needs additional funding to carry out research and clinical development; management has identified substantial doubt about its ability to continue as a going concern.
- 2Relies on partners such as Boehringer Ingelheim and Altanispac Labs to advance licensed medicines; payments beyond initial fees depend on future development, regulatory and sales milestones.
- 3Relies on outside manufacturers, suppliers and research organizations for drug materials, manufacturing and studies.
Qué podría salir mal
- 1Palatin may be unable to raise the money needed to continue operations and develop its drug candidates.
- 2Its main internally funded obesity candidates are at an early stage, and clinical studies or regulatory review may fail to support their use as medicines.
- 3Partner-led programs may not advance or produce milestone payments and royalties if collaborators do not develop or commercialize the medicines successfully.
Estados financieros completos →
Sobre Palatin Technologies Inc.
Palatin's main in-house work targets the melanocortin 4 receptor (MC4R), which is involved in appetite and body weight, with injectable and oral drug candidates for rare obesity disorders. It also develops or licenses medicines aimed at inflammatory diseases, including eye and bowel conditions. Its former approved drug Vyleesi was acquired by Cosette in 2023; Palatin now seeks income from licensing, research funding, milestone payments and, if licensed medicines reach the market, royalties.
- Sede
- Princeton, New Jersey, United States
- Fundada en
- 1986 (incorporated; biopharmaceutical operations began in 1996)
- Empleados
- 25 (September 25, 2026, high)
- Cotiza en
- Nasdaq Capital Market
- Cierre del ejercicio
- June 30
Construido a partir de los propios informes de Palatin Technologies Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
